The first targeted therapy for metastatic bladder cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Patients should be selected for therapy with Balversa using an FDA-approved companion diagnostic device.
To continue reading this article
Continue reading your article with a Emedinexus account..